INS and Hyperglycemia: We found that STZ-treated mice developed sustained hyperglycemia within 1 week, and grafting with either null-MSCs or as-miR-205-5p-MSCs did not reserve hyperglycemia (Figure 5B), which were supported by beta cell mass quantification (Figure 5C), demonstrated by representative immunostaining images for insulin (Figure 5D).